Current Headlines

  1. Research Opens Up New Avenue For Tuberculosis Drug Discovery 7/3/2025

    Researchers investigating the structure and function of the TB enzyme MCR have identified several possible new drug candidates for treating TB.

  2. Forging A Novel Therapeutic Path For Patients With Rett Syndrome Using AI 7/2/2025

    Rett syndrome is a devastating, rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are born with it, and much fewer boys.

  3. Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval For Treatment Of Relapsed Or Refractory Multiple Myeloma 7/2/2025

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody.

  4. Optibrium Partners With TalTech On EU-Funded PhD Programme To Advance Sustainable Drug Discovery 7/2/2025

    Optibrium, a leading developer of software and AI solutions for molecular design, today announced its partnership with TalTech (Tallinn University of Technology) to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme.

  5. Quiver Bioscience Secures Non-Dilutive Funding To Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities And Advance Powerful AI/ML-Based In Vitro / In Silico Predictor Of CNS Drug Safety 7/1/2025

    Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, today announced receipt of a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

  6. Healx And SCI Ventures Join Forces To Uncover Cures For Paralysis With AI-Driven Drug Discovery 7/1/2025

    Healx, a pioneer in AI-powered drug discovery for rare and neglected conditions, has partnered with SCI Ventures - the world’s first specialist venture fund focused on curing paralysis- to accelerate the discovery and development of therapies for spinal cord injury (SCI) using artificial intelligence.

  7. Rocket Pharmaceuticals Announces FDA IND Clearance Of RP-A701 For The Treatment Of BAG3-Associated Dilated Cardiomyopathy 6/30/2025

    Rocket Pharmaceuticals, Inc., a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-associated Dilated Cardiomyopathy (BAG3-DCM), a severe form of heart failure characterized by progressive ventricular enlargement and impaired systolic function.

  8. Riliprubart Granted Orphan Drug Designation In Japan For Chronic Inflammatory Demyelinating Polyneuropathy 6/30/2025

    The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to riliprubart, a monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway for people with chronic inflammatory demyelinating polyneuropathy (CIDP). Despite available therapies, many CIDP patients are left with residual symptoms, including weakness, numbness, and fatigue that can lead to long-term morbidity and diminished quality of life. Approximately 30% of people with CIDP do not respond to standard therapies.

  9. Alpha Fusion, Inc. And Curadh MTR, Inc. To Enter Into Strategic Partnership To Advance Global Development Of Astatine-211 Based Radiopharmaceuticals 6/30/2025

    Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration combines Alpha Fusion's leading role in At-211 drug discovery and early clinical work in Japan, with Curadh's global expertise in radiopharmaceutical development.

  10. XtalPi And Pfizer Expand Strategic Collaboration To Advance AI-Driven Drug Discovery And Materials Science Simulations 6/29/2025

    XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with Pfizer to pioneer a next-generation molecular modeling platform for drug discovery.